← feed

Is NCT02468661 results overdue?

Yes — results are overdue. Primary completion was 2017-11-15; the FDAAA-801 reporting deadline (2018-11-15) passed 2775 days ago and no results are posted on ClinicalTrials.gov.

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

NCT IDNCT02468661 ↗
SponsorNovartis Pharmaceuticals (INDUSTRY)
Public issuerNOVARTIS AG — NVS (CIK 0001114448) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusTERMINATED
Primary completion2017-11-15 (ACTUAL)
Reporting deadline2018-11-15 (completion + 365d)
Days overdue2775
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 0377cb115683bfe3… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02468661. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →